Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where N. Zivkovic is active.

Publication


Featured researches published by N. Zivkovic.


European Neuropsychopharmacology | 2012

P.3.016 Oxcarbazepine, topiramate and lamotrigine in the treatment of alcohol craving

B. Bajovic; N. Zivkovic; G. Djokic; D. Pavicevic

The significance of differences between average measurements in the two groups was assessed using Student’s t-test. Significance was set at p< 0.05. Statistical analysis was performed using the STATA Data Analyses Tool: Regression statistics; Two-sample t test with equal variances, Bartlett’s test for equal variances, Bonferroni test. Results: The levels of vitamin B12 and folic acid were found to be normal for all patients. The mean level of Hcy was 11.94±5.6mmol/L for patients with schizophrenia spectrum disorders and 11.26±3.3mmol/L for patients with affective disorders versus 7.47±2.9mmol/L for controls. The highest level of Hcy in the schizophrenia patients was seen in those with an episodic-recurrent disease course, in particular for acute onset and pronounced affect. For the group with affective disorders the highest level was seen in patients with depressive symptoms with anxiety and in patients with mixed affective disorders (r = −0.58; p< 0.01). No associations were found between patient groups, the level of Hcy and MTHFR gene polymorphism. Conclusions: These data suggest a potential link between Hcy level and pronounced affect in schizophrenia and affective disorders, as well as disease severity and course. However, no association was found between Hcy level, schizophrenia and affective disorders and the MTHFR 677C→T polymorphism.


European Neuropsychopharmacology | 2014

P.1.k.030 Demographic characteristics of super-responders on treatment with atypical antipsychotics

A. Kuzmanovic; N. Zivkovic; D. Pavicevic; G. Djokic; K. Zoric


European Neuropsychopharmacology | 2011

P.3.c.011 Risperidone and olanzapine in treatment of delusional disorders

N. Zivkovic; G. Djokic; D. Pavicevic; B. Bajovic; M. Ilic; M. Tomic; J. Lekovic


European Neuropsychopharmacology | 2010

P.2.c.016 Sertraline versus mirtazapine in treatment of depression in Parkinson's disease

G. Djokic; D. Pavicevic; N. Zivkovic; M. Nenadovic; N. Nenadovic; D. Duisin


European Neuropsychopharmacology | 2015

P.3.d.035 Aripiprazole in treatment of first episode schizophrenia

A. Kuzmanovic; N. Zivkovic; G. Djokic; D. Curcic; K. Zoric; M. Djordjevic


European Neuropsychopharmacology | 2014

P.1.g.017 Behavioural and psychological signs of dementia: is there a need for short-term antipsychotic treatment?

A. Kuzmanovic; G. Djokic; N. Zivkovic; D. Pavicevic; K. Zoric


European Neuropsychopharmacology | 2011

P.3.c.010 Combination of clozapine and escitalopram in treatment of negative symptoms in residual schizophrenia

N. Zivkovic; B. Bajovic; G. Djokic; D. Pavicevic; M. Ilic; M. Tomic; J. Lekovic


European Neuropsychopharmacology | 2010

P.3.027 Oxcarbazepine, gabapentin and lamotrigine in treatment of heroin craving

N. Zivkovic; D. Pavicevic; G. Djokic


European Neuropsychopharmacology | 2010

P.3.c.028 Olanzapine in treatment of delusional disorders

N. Zivkovic; D. Pavicevic; G. Djokic; M. Nenadovic; N. Nenadovic; J. Lekovic


European Neuropsychopharmacology | 2009

P.6.e.003 Effect of sigarette smoking on treatment of schizophrenia with clozapine

N. Zivkovic; D. Pavicevic; G. Djokic; J. Lekovic

Collaboration


Dive into the N. Zivkovic's collaboration.

Researchain Logo
Decentralizing Knowledge